Background Data on the effect of initial combination therapy with ambrisentan and tadalafil
on long-term outcomes in patients with pulmonary arterial hypertension are scarce. Methods …

… Correspondence and requests for reprints should be addressed to Andrew J. Peacock, MD,
Scottish Pulmonary Vascular Unit, Level 1, Golden Jubilee National Hospital, Agamemnon …

Rationale: Pulmonary arterial hypertension in association with connective tissue disease (CTD-PAH)
has historically had a poor prognosis, with a 1-year survival rate among patients …

Registries of patients with pulmonary arterial hypertension (PAH) have been instrumental in
characterizing the presentation and natural history of the disease and provide a basis for …

Background— By its inhibitory effect on platelet-derived growth factor signaling, imatinib
could be efficacious in treating patients with pulmonary arterial hypertension (PAH). Methods …

Pulmonary hypertension (PH) frequently complicates the course of patients with various forms
of chronic lung disease (CLD). CLD-associated PH (CLD-PH) is invariably associated with …

Rationale: The management of chronic thromboembolic pulmonary hypertension (CTEPH)
has changed over recent years with the growth of pulmonary endarterectomy surgery and the …

Rationale: Pulmonary arterial hypertension (PAH) is a progressive condition with a poor
prognosis. Platelet-derived growth factor receptor (PDGFR) signaling plays an important role in …

The number of people travelling to the high altitude regions, especially South America,
Nepal, and India, has risen enormously in the past 10 years. Without special climbing ability …

Pulmonary arterial hypertension (PAH) is a rare disorder with a poor prognosis. Deleterious
variation within components of the transforming growth factor-β pathway, particularly the …